Bausch Health Q2 2026 slides: 13th straight growth quarter, guidance raised By Investing.com
Bausch Health (NYSE:BHC) reported Q2 2026 results on July 29, with adjusted EPS of $1.26 and revenue of $2.85B, beating forecasts. The company said adjusted EBITDA rose 28% to $1.08B and raised full-year 2026 guidance for Bausch excluding B+L. Shares rose to $4.68, up 3.65% in regular trading.
How this was made
The 30-second read
Why it matters
The key tradable update is the guidance increase alongside quantified second-half headwinds, which can drive revisions to expectations for margins, cash flow, and deleveraging pace.
Market read
Guidance raise plus beat metrics can extend momentum, but the disclosed second-half headwinds create a clear risk framework for the next earnings window.
What to watch
The article notes elevated debt-to-total capital (89%) and ongoing pricing pressure; traders may need to watch whether margin expansion continues into the second half.
Background
Bausch Health reported its 13th consecutive quarter of revenue and adjusted EBITDA growth and used the Q2 deck to raise 2026 full-year guidance.
Ticker impact
Bausch Health reported Q2 2026 results and raised full-year guidance, with adjusted EPS $1.26 and revenue $2.85B beating forecasts.
Likely continued post-earnings support, with volatility around second-half headwinds and margin durability.
The article provides specific beat metrics and explicit guidance increases, plus quantified second-half headwinds ($275M) that can cap upside.
Market effects
Signals resilience in branded pharma/gastro and aesthetics franchises despite generic and reimbursement pressure.
EMEA organic growth streak (14 consecutive quarters) supports confidence in international demand.
Deleveraging progress and margin expansion may influence sentiment toward leveraged specialty pharma balance sheets globally.
Counterpoint
Second-half headwinds are explicitly quantified ($275M), so the guidance raise may already be priced in while downside risk persists in Aplenzin and reimbursement channels.
Key entities
- companyBausch Health Companies Inc.
Subject of the article; raised 2026 guidance after Q2 2026 earnings beat and strong cash generation.
- business_segmentSalix
Reported 21% revenue growth in Q2, led by Xifaxan demand and net realized price increases.
- business_segmentBausch + Lomb
Reported balanced growth across vision care, surgical, and pharmaceuticals divisions.
